US FDA's final guidance provides more examples of data that meets the 'scientifically appropriate and statistically sound' standard.
The US FDA is providing more details on the kinds of information that firms can communicate about their products that would be consistent with FDA-required labeling in a final guidance.
The document, "Medical Product Communications That Are Consistent with the FDA-Required Labeling – Questions and Answers," is similar to...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
